Clinical Trial RTOG 0920
- A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
- Principal Investigator
- Bharat Mittal
- Status: Accepting New Patients
- Study Type: Therapeutic, Treatment
- Protocol No:.RTOG 0920
- The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone versus radiation therapy and cetuximab on head and neck cancer after surgery.
- It is standard treatment to remove head and/or neck tumors surgically when able to do so. After surgery it is common to have radiation therapy to help stop tumors from growing back or spreading to other parts of the body. Cetuximab is a drug that may slow down or prevent tumor growth. It works by blocking certain pathways that lead to tumor growth. This study will see if the addition of this drug with radiation therapy can improve overall outcomes over radiation alone.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have had surgery for a head and/or neck tumor.
- Participants with primary hypopharynx tumors are not eligible.
- Description of Treatment
- There are two groups in this study, Group 1 and Group 2. Participants will be randomized like flipping a coin)into one or the other group. Both groups will receive radiation therapy for about 6 weeks. Group 2 will be given cetuximab intravenously (through a vein) once a week and may receive up to 11 doses.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Bharat Mittal
- Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
- Randomized Phase II And Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
last updated: 16-Jan-17 08:49 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.